TB-500 and thymosin beta-4: what the research shows
Thymosin beta-4 is a natural 43-amino-acid repair protein released by platelets at the site of an injury, and TB-500 is the shorter synthetic fragment of it. Here is what the human trials of the full-length protein found.
Findings
- In a phase 2 randomized trial in severe dry eye, ocular discomfort fell 35.1 per cent against vehicle control at day 56 (p=0.0141).
- Corneal staining, the objective sign of surface damage, fell 59.1 per cent against control in the same trial (p=0.0108).
- Tear film breakup time and tear volume both improved, and the improvements held 28 days after treatment stopped.
- In two phase 2 trials in stasis and pressure ulcers, thymosin beta-4 accelerated healing by almost a month in the patients who healed.
- It accelerated repair of full-thickness wounds across several animal models, including diabetic, steroid-treated and aged animals.
Severe dry eye: signs and symptoms both moved (Cornea, 2015)
A multicentre, randomized, double-masked, placebo-controlled phase 2 trial at two United States sites treated patients with severe dry eye disease, including dry eye associated with graft-versus-host disease, with thymosin beta-4 eye drops at 0.1 per cent or vehicle control, six times a day for 28 days, then followed them for a further 28. At day 56 the treated group showed a 35.1 per cent reduction in ocular discomfort on the standard questionnaire against control (p=0.0141), and a 59.1 per cent reduction in total corneal fluorescein staining (p=0.0108). Tear film breakup time and tear volume production also improved. The trial was small, twelve treated eyes against six control, but it moved both what patients reported and what examiners could measure, and the difference was still there a month after dosing ended.
A second dry eye trial, run in a controlled chamber (Clin Ophthalmol, 2015)
The same group ran a separate randomized, placebo-controlled phase 2 trial using a controlled adverse environment chamber, a setup that exposes participants to standardised drying conditions so that responses can be compared without weather and indoor air confounding them. It is an unusual level of experimental control for a peptide at this stage, and it was published the same year as the trial above.
Chronic wounds: two phase 2 trials (Ann N Y Acad Sci, 2012)
Thymosin beta-4 is released by platelets at the site of an injury and starts the repair cascade, which is why the wound work followed. It accelerated healing of full-thickness punch wounds across animal models chosen for being hard cases: normal rats and mice, steroid-treated rats, diabetic mice and aged mice. In two phase 2 clinical trials, in stasis ulcers and pressure ulcers, it accelerated healing by almost a month in those patients who healed. The review attributes the effect to several actions running together: promoting cell migration, mobilising stem cells, and damping inflammation.
What TB-500 is, and what it is not
Thymosin beta-4 is the full-length natural protein, 43 amino acids long, and it is the molecule used in every trial above. TB-500 is a shorter synthetic fragment containing the actin-binding sequence that is thought to carry much of the activity, and it is the form supplied as a research material. The two are related but not identical, so the trial figures on this page belong to the full-length protein. Our reconstitution guide covers handling of the vialled material.
Vistara Labs stocks TB-500 research vials, a ready-mixed TB-500 nasal spray and the BPC-157 with TB-500 blend, shipped from within Canada to every province.
Frequently asked questions
Has thymosin beta-4 been tested in humans?
Yes. Phase 2 randomized trials have been run in severe dry eye disease, and two phase 2 trials were run in stasis and pressure ulcers. The molecule in those trials is full-length thymosin beta-4, the natural 43-amino-acid protein.
What did the dry eye trial measure?
At day 56, the treated group showed a 35.1 per cent reduction in ocular discomfort against vehicle control (p=0.0141) and a 59.1 per cent reduction in corneal fluorescein staining (p=0.0108), with improvements in tear film breakup time and tear volume.
How does TB-500 relate to thymosin beta-4?
TB-500 is the shorter synthetic fragment of thymosin beta-4 that carries the actin-binding sequence. The human trials used the full-length natural protein, so results belong to that molecule, and the fragment is the research material.
Sources: Sosne G, Ousler GW. Thymosin beta 4 ophthalmic solution for dry eye: a randomized, placebo-controlled, phase II clinical trial conducted using the controlled adverse environment (CAE) model. Clin Ophthalmol. 2015;9:877-84. PMID 26056426. Sosne G, et al. Thymosin beta 4 significantly improves signs and symptoms of severe dry eye in a phase 2 randomized trial. Cornea. 2015;34:491-6. PMID 25826322. Treadwell T, et al. The regenerative peptide thymosin beta 4 accelerates the rate of dermal healing in preclinical animal models and in patients. Ann N Y Acad Sci. 2012;1270:37-44. PMID 23050815. Goldstein AL, Kleinman HK. Advances in the basic and clinical applications of thymosin beta 4. Expert Opin Biol Ther. 2015;15 Suppl 1:S139-45. PMID 26096726.
All products supplied by Vistara Labs are intended for laboratory research use only. They are not drugs, are not approved for human or veterinary use, and are not intended to diagnose, treat, cure or prevent any condition. Nothing on this page constitutes medical advice or guidance for use in humans.